Literature DB >> 26775808

Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter.

Haiyan Ji1, Zhengtao Jiang1, Panpan Lu1, Li Ma2, Chuan Li2, Hanyu Pan1, Zheng Fu1, Xiying Qu1, Pengfei Wang1, Junxiao Deng1, Xinyi Yang1, Jianhua Wang2, Huanzhang Zhu1.   

Abstract

HIV-1 escapes antiretroviral agents by integrating into the host DNA and forming a latent transcriptionally silent HIV-1 provirus. Transcriptional activation is prerequisite for reactivation and the eradication of latent HIV-1 proviruses. dCas9-SunTag-VP64 transcriptional system has been reported that it can robustly activate the expression of an endogenous gene using a single guide RNA (sgRNA). Here, we systematically investigated the potential of dCas9-SunTag-VP64 with the designed sgRNAs for reactivating latent HIV-1. We found dCas9-SunTag-VP64 with sgRNA 4 or sgRNA 5 targeted from -164 to -146 or -124 to -106 bp upstream of the transcription start sites of HIV-1 could induce high expression of luciferase reporter gene after screening of sgRNAs targeting different regions of the HIV-1 promoter. Further, we confirmed that dCas9-SunTag-VP64 with sgRNA 4 or sgRNA 5 can effectively reactivate latent HIV-1 transcription in several latently infected human T-cell lines. Moreover, we confirmed that the reactivation of latent HIV-1 by dCas9-SunTag-VP64 with the designed sgRNA occurred through specific binding to the HIV-1 LTR promoter without genotoxicity and global T-cell activation. Taken together, our data demonstrated dCas9-SunTag-VP64 system can effectively and specifically reactivate latent HIV-1 transcription, suggesting that this strategy could offer a novel approach to anti-HIV-1 latency.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26775808      PMCID: PMC4786936          DOI: 10.1038/mt.2016.7

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

1.  Positive and negative regulation of endogenous genes by designed transcription factors.

Authors:  R R Beerli; B Dreier; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.

Authors:  P Wei; M E Garber; S M Fang; W H Fischer; K A Jones
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

3.  HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.

Authors:  Albert Jordan; Dwayne Bisgrove; Eric Verdin
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

4.  HIV-1 Tat protein trans-activates transcription in vitro.

Authors:  R A Marciniak; B J Calnan; A D Frankel; P A Sharp
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

5.  Human zinc fingers as building blocks in the construction of artificial transcription factors.

Authors:  Kwang-Hee Bae; Young Do Kwon; Hyun-Chul Shin; Moon-Sun Hwang; Eun-Hyun Ryu; Kyung-Soon Park; Hyo-Young Yang; Dong-Ki Lee; Yangsoon Lee; Jinwoo Park; Heung Sun Kwon; Hyun-Won Kim; Byung-Il Yeh; Hyean-Woo Lee; Soon Hyung Sohn; Joonho Yoon; Wongi Seol; Jin-Soo Kim
Journal:  Nat Biotechnol       Date:  2003-02-18       Impact factor: 54.908

6.  High-affinity binders selected from designed ankyrin repeat protein libraries.

Authors:  H Kaspar Binz; Patrick Amstutz; Andreas Kohl; Michael T Stumpp; Christophe Briand; Patrik Forrer; Markus G Grütter; Andreas Plückthun
Journal:  Nat Biotechnol       Date:  2004-04-18       Impact factor: 54.908

7.  Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.

Authors:  E J Duh; W J Maury; T M Folks; A S Fauci; A B Rabson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue.

Authors:  Angélique Biancotto; Jean-Charles Grivel; Françoise Gondois-Rey; Lise Bettendroffer; Robert Vigne; Stephen Brown; Leonid B Margolis; Ivan Hirsch
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.

Authors:  Nathalia Holt; Jianbin Wang; Kenneth Kim; Geoffrey Friedman; Xingchao Wang; Vanessa Taupin; Gay M Crooks; Donald B Kohn; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2010-07-02       Impact factor: 54.908

10.  A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation.

Authors:  N D Perkins; N L Edwards; C S Duckett; A B Agranoff; R M Schmid; G J Nabel
Journal:  EMBO J       Date:  1993-09       Impact factor: 11.598

View more
  29 in total

Review 1.  Genome-Editing Technologies: Principles and Applications.

Authors:  Thomas Gaj; Shannon J Sirk; Sai-Lan Shui; Jia Liu
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

Review 2.  Barriers for HIV Cure: The Latent Reservoir.

Authors:  Sergio Castro-Gonzalez; Marta Colomer-Lluch; Ruth Serra-Moreno
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-28       Impact factor: 2.205

3.  A CRISPR Approach for Reactivating Latent HIV-1.

Authors:  Angel Lin; Zachary Klase
Journal:  Mol Ther       Date:  2016-03       Impact factor: 11.454

4.  Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.

Authors:  Will Dampier; Neil T Sullivan; Joshua Chang Mell; Vanessa Pirrone; Garth D Ehrlich; Cheng-Han Chung; Alexander G Allen; Mathew DeSimone; Wen Zhong; Katherine Kercher; Shendra Passic; Jean W Williams; Zsofia Szep; Kamel Khalili; Jeffrey M Jacobson; Michael R Nonnemacher; Brian Wigdahl
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-27       Impact factor: 2.205

Review 5.  CRISPR/Cas technology as a promising weapon to combat viral infections.

Authors:  Carmen Escalona-Noguero; María López-Valls; Begoña Sot
Journal:  Bioessays       Date:  2021-02-11       Impact factor: 4.345

Review 6.  Targeting HIV-1 proviral transcription.

Authors:  Alex Olson; Binita Basukala; Wilson W Wong; Andrew J Henderson
Journal:  Curr Opin Virol       Date:  2019-08-29       Impact factor: 7.121

7.  Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants.

Authors:  Will Dampier; Neil T Sullivan; Cheng-Han Chung; Joshua Chang Mell; Michael R Nonnemacher; Brian Wigdahl
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

8.  Rewiring Calcium Signaling for Precise Transcriptional Reprogramming.

Authors:  Nhung Thi Nguyen; Lian He; Margarita Martinez-Moczygemba; Yun Huang; Yubin Zhou
Journal:  ACS Synth Biol       Date:  2018-03-06       Impact factor: 5.110

9.  Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.

Authors:  Julia K Bialek; Gábor A Dunay; Maike Voges; Carola Schäfer; Michael Spohn; Rolf Stucka; Joachim Hauber; Ulrike C Lange
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

10.  The variances of Sp1 and NF-κB elements correlate with the greater capacity of Chinese HIV-1 B'-LTR for driving gene expression.

Authors:  Di Qu; Chuan Li; Feng Sang; Qiang Li; Zhi-Qiang Jiang; Li-Ran Xu; Hui-Jun Guo; Chiyu Zhang; Jian-Hua Wang
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.